Get the Stockscreener App
20.44
10.85%
2.00
Nanobiotix Adr stock is traded at $20.44, with a volume of 155.23K.
It is up +10.85% in the last 24 hours and up +8.21% over the past month.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
See More
Previous Close:
$18.44
Open:
$20.45
24h Volume:
155.23K
Relative Volume:
2.09
Market Cap:
$979.00M
Revenue:
$27,600
Net Income/Loss:
$-36.04M
P/E Ratio:
-25.65
EPS:
-0.7968
Net Cash Flow:
$-1.66M
1W Performance:
+6.46%
1M Performance:
+8.21%
6M Performance:
+502.95%
1Y Performance:
+391.35%
1-Day Range:
$20.01
$20.88
1-Week Range:
$14.78
$20.88
52-Week Range:
$2.76
$30.35
Nanobiotix Adr Stock (NBTX) Company Profile
Compare NBTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBTX
Nanobiotix Adr
|
20.42 | 889.09M | 27,600 | -36.04M | -1.66M | -0.7968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.79 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
655.88 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.12 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
812.69 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.06 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Nanobiotix Adr Stock (NBTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-24 | Initiated | Guggenheim | Buy |
| Dec-08-23 | Initiated | Leerink Partners | Outperform |
| Jan-06-21 | Initiated | Evercore ISI | Outperform |
Nanobiotix Adr Stock (NBTX) Latest News
Carter's, Newmont Corporation And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga
Nanobiotix (NASDAQ:NBTX) Shares Gap DownTime to Sell? - MarketBeat
Nanobiotix provides update on JNJ-1900 after Johnson & Johnson transfer - TipRanks
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Karooooo Posts Downbeat Earnings, Joins ASP Isotopes And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Orion, Nio, Alibaba Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Why Ericsson Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Why NioCorp Developments Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - inkl
Nanobiotix (NASDAQ:NBTX) Trading Up 19.2%Here's Why - MarketBeat
Nanobiotix (NASDAQ:NBTX) Shares Down 12%Should You Sell? - MarketBeat
Nanobiotix (NASDAQ:NBTX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Nanobiotix (NASDAQ:NBTX) Shares Gap UpHere's Why - MarketBeat
Morning Market Movers: XBIO, UPC, GLTO Spark Big Moves - RTTNews
FY2027 EPS Estimates for Nanobiotix Boosted by HC Wainwright - Defense World
Nanobiotix SA ADR Reports Revenue Surge Amid Strategic Advances - TipRanks
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket - inkl
Morning Market Movers: SPRC, VALN, NBY, And Other Gainers & Losers - RTTNews
Nanobiotix (NASDAQ:NBTX) Reaches New 1-Year HighHere's Why - MarketBeat
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC - GlobeNewswire Inc.
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Nanobiotix (NASDAQ:NBTX) Hits New 52-Week HighHere's Why - MarketBeat
Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) Short Interest Up 23.7% in August - MarketBeat
Nanobiotix (NASDAQ:NBTX) Trading 11.8% HigherTime to Buy? - MarketBeat
Biotech Stocks Moving Premarket: QLGN, MBX, HSDT, And Other Gainers & Losers - RTTNews
Nanobiotix (NASDAQ:NBTX) Shares Up 5.7%What's Next? - MarketBeat
Nanobiotix announces new results from JNJ-1900 study - TipRanks
Nanobiotix Announces Voting Rights and Share Capital Update - The Globe and Mail
Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.2% – Here’s Why - Defense World
Nanobiotix (NASDAQ:NBTX) Stock Price Up 2.9% – Should You Buy? - Defense World
Guggenheim Reaffirms Their Buy Rating on Nanobiotix (NBTX) - The Globe and Mail
Nanobiotix (NASDAQ:NBTX) Stock Price Down 2.5% – Should You Sell? - Defense World
Nanobiotix announces regulatory harmonization, new patent for JNJ-1900 - TipRanks
Nanobiotix Sa ADR Reports Q1 2025 Progress - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Guggenheim cuts Nanobiotix stock target to $8, maintains buy - Investing.com
Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study - Yahoo Finance
North America Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
Nanobiotix announces FDA issuance of Study May Proceed Letter for NBTXR3 study - TipRanks
What is the current Price Target and Forecast for Nanobiotix S.A.Sponsored ADR (NBTX) - Zacks Investment Research
Nanobiotix (NBTX) Stock Soared 107.9% on a Global Pharma Deal - AskTraders.com
Stock Market News and Commentary - Barchart.com
NanobiotixADR (NBTX) Stock Forecast & Price Prediction 2025–2030 - CoinCodex
Nanobiotix (NBTX) Short Interest Ratio and Volume 2025 - MarketBeat
Nanobiotix S.A.Sponsored ADR (NBTX) - Zacks Investment Research
NBTX News Today | Why did Nanobiotix stock go up today? - MarketBeat
Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat
Nanobiotix Adr Stock (NBTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):